Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study
Background: In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect prognosis should be considered when choosing therapy. We conducted a retrospective, single-center analysis in patients...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294221000733 |
| _version_ | 1819009492992393216 |
|---|---|
| author | Filipa Pontes Ana Rita Garcia Isabel Domingues M. João Sousa Rita Felix Cláudia Amorim Fábio Salgueiro Mónica Mariano Margarida Teixeira |
| author_facet | Filipa Pontes Ana Rita Garcia Isabel Domingues M. João Sousa Rita Felix Cláudia Amorim Fábio Salgueiro Mónica Mariano Margarida Teixeira |
| author_sort | Filipa Pontes |
| collection | DOAJ |
| description | Background: In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect prognosis should be considered when choosing therapy. We conducted a retrospective, single-center analysis in patients treated with first line platinum and antiEGFR antibody-containing regimen. The objective was to generate real-world data considering treatment outcomes and to identify predictors of survival. Patients/methods: Clinical charts of patients treated with cetuximab and platinum-based chemotherapy (CT) for R/M HNSCC in first-line setting, between January-2009 and December-2018 were assessed. In these 103 patients, the prognostic value of site of the primary tumor, age at diagnosis, gender, Cetuximab induced skin toxicity and prior treatments were studied multivariately. To evaluate progression free survival (PFS) and overall survival (OS), Kaplan-Meier curves and the log-rank test were used. The Coxregression model was used to investigate the effect of these variables on OS. Results: Longer OS was associated with oral cavity tumor location (p = 0,003), European Cooperative Oncology Group-Performance Status 0 (ECOG-PS) (p = 0,01), complete/partial response (p<0,0001), cetuximab monotherapy until disease progression or unacceptable toxicity (p = 0,037) and Grade 2–4 cetuximab induced skin toxicity (p = 0,037). The median follow-up period was 11,7 months. The mortality rate was 90,3% during this retrospective cohort assessment. The PFS was 7,1 months (95% confidence interval (CI), 5,6–8.6). The OS was 11,7 months (95%CI, 10,5–12,8). Conclusions: The present study demonstrates that the combination of cetuximab with platinum-based CT was effective in R/M HNSCC. Among patients with R/M HSCC treated with platinum plus cetuximab as first-line therapy, primary site, ECOG-PS, grade 2–4 cetuximab induced toxicity, and weekly cetuximab monotherapy have a marked impact on OS. |
| first_indexed | 2024-12-21T00:57:14Z |
| format | Article |
| id | doaj.art-c2413b6f4b8a4f3796770ed830be6105 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-21T00:57:14Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-c2413b6f4b8a4f3796770ed830be61052022-12-21T19:21:16ZengElsevierCancer Treatment and Research Communications2468-29422021-01-0127100375Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective studyFilipa Pontes0Ana Rita Garcia1Isabel Domingues2M. João Sousa3Rita Felix4Cláudia Amorim5Fábio Salgueiro6Mónica Mariano7Margarida Teixeira8Corresponding author: Contact number: (00351) 239 400 200.; Instituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalInstituto Português de Oncologia de Coimbra Francisco Gentil Av. Prof. Dr. Bissaya Barreto n.º 98, 3000-075 Coimbra PortugalBackground: In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect prognosis should be considered when choosing therapy. We conducted a retrospective, single-center analysis in patients treated with first line platinum and antiEGFR antibody-containing regimen. The objective was to generate real-world data considering treatment outcomes and to identify predictors of survival. Patients/methods: Clinical charts of patients treated with cetuximab and platinum-based chemotherapy (CT) for R/M HNSCC in first-line setting, between January-2009 and December-2018 were assessed. In these 103 patients, the prognostic value of site of the primary tumor, age at diagnosis, gender, Cetuximab induced skin toxicity and prior treatments were studied multivariately. To evaluate progression free survival (PFS) and overall survival (OS), Kaplan-Meier curves and the log-rank test were used. The Coxregression model was used to investigate the effect of these variables on OS. Results: Longer OS was associated with oral cavity tumor location (p = 0,003), European Cooperative Oncology Group-Performance Status 0 (ECOG-PS) (p = 0,01), complete/partial response (p<0,0001), cetuximab monotherapy until disease progression or unacceptable toxicity (p = 0,037) and Grade 2–4 cetuximab induced skin toxicity (p = 0,037). The median follow-up period was 11,7 months. The mortality rate was 90,3% during this retrospective cohort assessment. The PFS was 7,1 months (95% confidence interval (CI), 5,6–8.6). The OS was 11,7 months (95%CI, 10,5–12,8). Conclusions: The present study demonstrates that the combination of cetuximab with platinum-based CT was effective in R/M HNSCC. Among patients with R/M HSCC treated with platinum plus cetuximab as first-line therapy, primary site, ECOG-PS, grade 2–4 cetuximab induced toxicity, and weekly cetuximab monotherapy have a marked impact on OS.http://www.sciencedirect.com/science/article/pii/S2468294221000733Head and neck cancer survival predictors toxicity |
| spellingShingle | Filipa Pontes Ana Rita Garcia Isabel Domingues M. João Sousa Rita Felix Cláudia Amorim Fábio Salgueiro Mónica Mariano Margarida Teixeira Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study Cancer Treatment and Research Communications Head and neck cancer survival predictors toxicity |
| title | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study |
| title_full | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study |
| title_fullStr | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study |
| title_full_unstemmed | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study |
| title_short | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study |
| title_sort | survival predictors and outcomes of patients with recurrent and or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first line therapy a real world retrospective study |
| topic | Head and neck cancer survival predictors toxicity |
| url | http://www.sciencedirect.com/science/article/pii/S2468294221000733 |
| work_keys_str_mv | AT filipapontes survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT anaritagarcia survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT isabeldomingues survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT mjoaosousa survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT ritafelix survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT claudiaamorim survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT fabiosalgueiro survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT monicamariano survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy AT margaridateixeira survivalpredictorsandoutcomesofpatientswithrecurrentandormetastaticheadandneckcancertreatedwithchemotherapypluscetuximabasfirstlinetherapyarealworldretrospectivestudy |